This Article Full Text Full Text (PDF) All Versions of this Article: 47/4/665    most recent 01.HYP.0000205831.39339.a5v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chai, W. Articles by Jan Danser, A.H. Search for Related Content PubMed PubMed Citation Articles by Chai, W. Articles by Jan Danser, A.H. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB SPIRONOLACTONE Related Collections Contractile function Cardiovascular Pharmacology Receptor pharmacology Animal models of human disease Arrythmias-basic studies

(Hypertension. 2006;47:665.)
© 2006 American Heart Association, Inc.

Original Articles

Cardioprotective Effects of Eplerenone in the Rat Heart

Interaction With Locally Synthesized or Blood-Derived Aldosterone?

From the Department of Pharmacology, Erasmus MC, Rotterdam, the Netherlands.

Correspondence to A.H. Jan Danser, Department of Pharmacology, Rm EE1418b, Erasmus MC, Dr. Molewaterplein 50, 3015 GE Rotterdam, the Netherlands. E-mail a.danser{at}erasmusmc.nl

Mineralocorticoid receptor antagonism with eplerenone reduces mortality in heart failure, possibly because of blockade of the deleterious effects of aldosterone. To investigate these effects, rat Langendorff hearts were exposed to aldosterone and/or eplerenone. Under normal conditions, aldosterone increased left ventricular pressure and decreased coronary flow. Eplerenone did not block these effects. Eplerenone reduced infarct size (from 68±2% to 53±4%; P<0.05) and increased left ventricular pressure recovery (from 44±2% to 60±5%; P<0.05) after 45 minutes of coronary artery occlusion and 3 hours of reperfusion, whereas aldosterone did not affect these parameters. To verify the origin of cardiac aldosterone, hearts were perfused with 3 to 30 nmol/L aldosterone and either frozen immediately or exposed to washout. Without washout, cardiac aldosterone was 1.5 times aldosterone in coronary effluent (CE), that is, too high to be explained on the basis of its presence in extracellular fluid. The cardiac levels of aldosterone correlated with its CE levels (r=0.81; P<0.01), and both were unaffected by eplerenone. During washout, tissue aldosterone disappeared monophasically (half life, 9±1 minutes), and CE aldosterone disappeared biphasically (half life 1±0 and 8±1 minutes, respectively). During buffer perfusion, cardiac aldosterone was at or below the detection limit. In conclusion, eplerenone improves the condition of the heart after ischemia and reperfusion. This does not relate to interference with the inotropic and vasoconstrictor effects of aldosterone. The majority of cardiac aldosterone, if not all, is derived from the circulation. The rapid, mineralocorticoid receptor-independent kinetics of aldosterone suggest that its accumulation in the heart involves cell surface binding rather than internalization.

Key Words: mineralocorticoids • blood flow • arrythmia • ischemia

This article has been cited by other articles:

				L. Michea, A. Villagran, A. Urzua, S. Kuntsmann, P. Venegas, L. Carrasco, M. Gonzalez, and E. T. Marusic Mineralocorticoid Receptor Antagonism Attenuates Cardiac Hypertrophy and Prevents Oxidative Stress in Uremic Rats Hypertension, August 1, 2008; 52(2): 295 - 300. [Abstract] [Full Text] [PDF]

				K. Graf, T. Hucko, and P. Stawowy Cardiac Benefits of Mineralocorticoid Receptor Inhibition in Renal Failure Hypertension, August 1, 2008; 52(2): 209 - 210. [Full Text] [PDF]

				T. Ohtani, M. Ohta, K. Yamamoto, T. Mano, Y. Sakata, M. Nishio, Y. Takeda, J. Yoshida, T. Miwa, M. Okamoto, et al. Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: beneficial effects of mineralocorticoid receptor blocker Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2007; 292(2): R946 - R954. [Abstract] [Full Text] [PDF]

				Wenxia Chai, Y. M Hoedemaekers, R. H. van Schaik, M. van Fessem, I. M Garrelds, J. J Saris, D. Dooijes, F. J ten Cate, M. M. Kofflard, and A. J. Danser Cardiac aldosterone in subjects with hypertrophic cardiomyopathy Journal of Renin-Angiotensin-Aldosterone System, December 1, 2006; 7(4): 225 - 230. [Abstract] [PDF]